Key statistics
As of last trade BioMarin Pharmaceutical Inc (1BMRN:MIL) traded at 59.90, 4.36% above its 52-week low of 57.40, set on Nov 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 59.38 |
---|---|
High | 59.90 |
Low | 59.38 |
Bid | 59.98 |
Offer | 63.34 |
Previous close | 59.54 |
Average volume | 2.22 |
---|---|
Shares outstanding | 190.58m |
Free float | 188.90m |
P/E (TTM) | 38.16 |
Market cap | 12.09bn USD |
EPS (TTM) | 1.66 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 08:06 GMT.
More ▼
Press releases
- BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
- BioMarin to Participate in Three Upcoming Investor Conferences
- BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
- BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
- BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
- BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
- BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
- BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
More ▼